Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer.
Several recent studies have revealed that microRNAs (miRNAs) have a role in carcinogenesis and cancer development, and that it is stably detectable in plasma/serum. The aim of this study was to test whether miR‑483-3p as well as miR‑21 could be plasma biomarkers for PDAC. The plasma samples were obtained from three groups including 32 pancreatic ductal adenocarcinoma (PDAC) patients, 12 patients with intraductal papillary mucinous neoplasm (IPMN) patients and 30 healthy controls (HC). We evaluated the plasma miR‑483-3p and miR‑21 expression level by quantitative RT-PCR. We compared the differences in the plasma level of these miRNAs among the three groups, and investigated the relevance of their plasma expression level to the clinical factors in PDAC. The expressions of miR‑483-3p and miR‑21 were detected in all examined plasma samples. The plasma expression levels of these miRNAs were significantly higher in PDAC compared to HC (P<0.01). The plasma miR‑483-3p expression was significantly higher in PDAC patients than IPMN patients (P<0.05). The plasma miR‑21 level was associated with advanced stage (P<0.05), metastasis to lymph node and liver (P<0.01), and shorter survival (P<0.01) of the PDAC patients. Together, these findings suggest that measurement of the plasma miR‑483-3p level is useful for discriminating PDAC from IPMN, and that the plasma miR‑21 level predicts outcome of PDAC patients.
Division of Cancer Stem Cell, Miyagi Cancer Center Research Institute, Natori, Miyagi 981-1293, Japan.
Makoto
M
Abue
Division of Cancer Stem Cell, Miyagi Cancer Center Research Institute, Natori, Miyagi 981-1293, Japan.
Misa
M
Yokoyama
Division of Cancer Stem Cell, Miyagi Cancer Center Research Institute, Natori, Miyagi 981-1293, Japan.
Rie
R
Shibuya
Division of Cancer Biology and Therapeutics, Miyagi Cancer Center Research Institute, Natori, Miyagi 981-1293, Japan.
Keiichi
K
Tamai
Division of Molecular and Cellular Oncology, Miyagi Cancer Center Research Institute, Natori, Miyagi 981-1293, Japan.
Kazunori
K
Yamaguchi
Department of Pathology, Miyagi Cancer Center, Medeshima Siote, Natori, Miyagi 981-1293, Japan.
Ikuro
I
Sato
Division of Cancer Biology and Therapeutics, Miyagi Cancer Center Research Institute, Natori, Miyagi 981-1293, Japan.
Nobuyuki
N
Tanaka
Division of Gastroenterology, Tohoku University Graduate School of Medicine, Aoba-ku, Sendai, Miyagi 980-8574, Japan.
Shin
S
Hamada
Division of Gastroenterology, Tohoku University Graduate School of Medicine, Aoba-ku, Sendai, Miyagi 980-8574, Japan.
Tooru
T
Shimosegawa
Division of Molecular and Cellular Oncology, Miyagi Cancer Center Research Institute, Natori, Miyagi 981-1293, Japan.
Kazuo
K
Sugamura
Division of Cancer Stem Cell, Miyagi Cancer Center Research Institute, Natori, Miyagi 981-1293, Japan.
Kennichi
K
Satoh
D000230:Adenocarcinoma / Q000097:blood / Q000235:genetics* / Q000473:pathology; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000097:blood / Q000235:genetics* / Q000473:pathology; D021441:Carcinoma, Pancreatic Ductal / Q000097:blood / Q000235:genetics* / Q000473:pathology; D003937:Diagnosis, Differential; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008198:Lymph Nodes; D008297:Male; D035683:MicroRNAs / Q000096:biosynthesis* / Q000097:blood; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000097:blood / Q000235:genetics* / Q000473:pathology
D014408:Biomarkers, Tumor; C524940:MIRN21 microRNA, human; C548912:MIRN483 microRNA, human; D035683:MicroRNAs